🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So proud to work with such talented and generous colleagues Duke Hematologic Malignancies & Cellular Therapy instagram.com/p/CY9EmR9rp-X/…

Freddie Andersen appreciation tweet

Wordle 226 3/6 ⬜⬜⬜⬜⬜ ⬜🟨⬜⬜⬜ 🟩🟩🟩🟩🟩

Final results of ph III #omidubicel vs UCB presented by Mitch Horwitz at ASTCT #Tandem22: trend towards 1y NRM benefit 15 v 29% (p=0.068), similar relapse rates, & maintained superiority in G2-3 bacterial/fungal and G3 viral infections. #BMTsm #leusm

What a fantastic technology that can really expand access to life-saving stem cell transplant procedures for underrepresented minority groups. Hope it’s approved! 🤞 #Omidubicel #bmtsm #healthdisparities

Our brief discussion w/ Targeted Oncology about Duke's 10-yr f/u of #omidubicel transplant outcomes from #ASH21 #Tandem22. International multicenter results will be presented at #SOHO22. Many thanks to Mitch Horwitz and Duke Hematologic Malignancies & Cellular Therapy for this opportunity! #bmtsm targetedonc.com/view/long-term…

Welcome Duke Dept of Medicine interns! We are so glad you are here and look forward to working with you. Thanks Dr. AimeeZaasDukeIMPD and Jenny Van Kirk for planning such a great retreat! Duke Department of Medicine

Thanks to ASH for bringing #ASH22 back to its pre-covid glory! After the amazing friends and abstracts, my other highlight was seeing our recent Transplantation and Cellular Therapy Journal QOL paper referenced at an education program. Always so fulfilling to discover someone has read your work.

BREAKING: U.S. FDA has approved #omidubicel for stem cell transplantation. Cord expansion is here! Tremendous congrats to Mitch Horwitz Duke Hematologic Malignancies & Cellular Therapy and Gamida Cell for this decade-long journey bringing the drug from bench to trials to patients. #bmtsm $GMDA fda.gov/news-events/pr…

WATCH: Dr Horwitz on the FDA Approval of Omidubicel in Blood Cancers Requiring Transplant Mitch Horwitz Duke Cancer Duke Regeneration Center U.S. FDA #oncology ow.ly/ro1R50NL4zu

Omidubicel is FDA approved: - Nicotinamide-expanded UCB - Age 12+ - Myeloablative conditioning - Median ANC 500 = 12 days - Median platelets 20K = 37 days - Fewer grade 2/3 infections than standard UCBT - GVHD: 56% grade II-IV, 14% grade III-IV, 35% chronic

ashpublications.org/blood/article/…

"The studies have shown that #omidubicel is associated with faster recovery of blood counts, a lower risk of infection, shorter hospital stays, and better quality of life compared to conventional cord blood transplants," Chenyu Lin, MD, of Duke University told us.

My latest “Letter From a Jail” to ⁦ABIM Foundation⁩ about the Board’s every-3-month Longitudinal Knowledge Assessments! They are DEFINITELY no vacation! 😡🩺 medpagetoday.com/opinion/second…

Thank you Mikkael- I could not agree more.

Eliminate ABIMs MOC requirement - Sign the Petition! chng.it/zrWqv7kj via Change.org

As a heme malignancy doc, answering questions on bladder cancer on a Saturday morning is infuriating. Having to do it in 4 minutes is an abomination. This must end!! Please sign.

Duke HMCT has received funding to continue as a core center for the NIH-sponsored Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Dr. Mitchell Horwitz (Mitch Horwitz) is the PI and leads the Duke Consortium including the UVA and Novant Health cell therapy programs.

NCI congressional justification released. $1.26 BILLION cut in research grants and a 15% indirect rate.